8-K: Cannabis Bioscience International Holdings Sells 250 Million Shares to Director in Conflicting Interest Transaction

Cannabis Bioscience International Holdings sold 250 million shares to a director, John Jones, for $75,000, with a repurchase agreement if the share value doesn't reach a certain level by the end of 2025.

Summary

• Cannabis Bioscience International Holdings, Inc. entered into a Stock Purchase Agreement with director John Jones on December 27, 2024.
• Mr. Jones purchased 250,000,000 shares of the company's common stock for a total of $75,000, which equates to $0.0003 per share.
• This transaction was considered a conflicting interest transaction under Colorado Revised Statutes, as Mr. Jones is a director.
• The board of directors approved the agreement after disclosing Mr. Jones's interest, with a majority of disinterested directors voting in favor.
• The agreement includes a covenant requiring the company to repurchase the shares if their market value is less than $93,750 on December 31, 2025.
• The company's repurchase obligation terminates if the average closing price of the shares exceeds $0.000375 per share on any day.
• If the repurchase is triggered, the company has the option to pay the difference in cash, issue new shares, or a combination of both, based on the average closing price on December 31, 2025.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the very low share price, the unusual repurchase agreement, and the conflicting interest nature of the transaction, indicating potential financial and governance issues.

Positives

• The company successfully raised $75,000 through the sale of shares.
• The agreement includes a mechanism to protect the investor's investment if the share price does not increase as expected.
• The board of directors followed proper procedures in approving the conflicting interest transaction.

Negatives

• The sale of shares at $0.0003 per share indicates a very low valuation of the company's stock.
• The repurchase agreement could create a significant financial obligation for the company if the share price does not increase.
• The transaction was a conflicting interest transaction, which could raise concerns about corporate governance.

Risks

• The company may be required to repurchase the shares for $93,750 if the market value is below that on December 31, 2025, which could strain its finances.
• The low share price and the need for a repurchase agreement suggest potential financial instability or lack of investor confidence.
• The conflicting interest nature of the transaction could lead to scrutiny from regulators or shareholders.

Future Outlook

The company's future financial obligations depend on the share price performance by December 31, 2025, with a potential repurchase obligation if the market value is below $93,750.

Management Comments

• The board of directors authorized the agreement after disclosure of Mr. Jones' interest, by a majority of the disinterested directors.

Industry Context

This transaction is specific to Cannabis Bioscience International Holdings and does not reflect broader industry trends, but it does highlight the challenges faced by smaller companies in the cannabis sector to raise capital.

Comparison to Industry Standards

• The share price of $0.0003 is significantly lower than the average share price of most publicly traded cannabis companies, indicating a high level of risk and low valuation.
• The repurchase agreement is unusual and suggests a lack of confidence in the company's short-term share price performance, which is not typical in standard stock purchase agreements.
• Compared to other companies, the transaction is not a standard capital raise, but rather a specific agreement with a director, which is not a common practice.

Related Party Transactions

• The stock purchase agreement with John Jones, a director of the company, is a related party transaction.

Stakeholder Impact

• Shareholders may be concerned about the low share price and the potential financial obligation of the repurchase agreement.
• Employees may be affected by the company's financial situation and the potential impact on its operations.
• Creditors may be concerned about the company's ability to meet its financial obligations.

Next Steps

• The company needs to monitor its share price to avoid triggering the repurchase obligation on December 31, 2025.
• The company may need to explore other financing options if the share price does not improve.
• The company should ensure full transparency and compliance with all regulations regarding the conflicting interest transaction.

Key Dates

Keywords

stock purchase agreement, cannabis bioscience international holdings, john jones, share repurchase, conflicting interest transaction, common stock, director, corporate governance